Redcentric Regulatory News (RCN)

Redcentric plc

("Redcentric" or the "Company")

Board Changes

Redcentric (AIM: RCN), a leading UK IT managed services provider, is pleased to announce the appointment of Ian Johnson as Non-Executive Chairman of the Company, following notification in August of Chris Cole's intention to stand down. Chris Cole will step down from his position as Chairman of Redcentric, effective immediately, and Ian will join the board of directors (the "Board") and take over as Chairman with immediate effect.

Ian has served on the boards of a number of public and private companies and has a strong track record in building shareholder value. He was founder and CEO of Biotrace International plc until December 2006, Non-Executive Chairman of Celsis Group Ltd from 2009 until 2015 and Chairman of Cyprotex plc until 2016. He was also Chairman of Quantum Pharma plc until 2017, and most recently Executive Chairman of Bioquell plc from 2016 until 2019. Ian was recently appointed as Non-Executive Director of Ergomed plc.

The Company further announces that Chris Rigg, Non-Executive Director, will step down from the Board with effect from 31 December 2019 following his appointment as Chief Executive Officer of Mandata Limited which commences in November 2019.

Peter Brotherton, Chief Executive Officer, commented:

"I am pleased to welcome Ian to Redcentric on behalf of the Board. Ian's wealth of experience will be of great benefit to the Company and we look forward to working with him. 

As stated on 20th August 2019, when the Chairman notified the Board of his intention to step down, I would like to again thank Chris, on behalf of the Board and all at Redcentric, for his counsel, guidance and leadership over the last five years and wish him all the best for the future. Chris has led the Board through a time of major change for the Company and leaves Redcentric in a stable position with a clearly defined strategy and opportunities for growth.

Finally, I would also like to thank Chris Rigg for his contribution to the Company this year and to wish him well in his new role.''

Chris Cole commented:

"Having helped lead the changes and progress of the Company it is now appropriate to hand over the Chairmanship. I wish the Company well for the future."

Ian Johnson commented:

"I am excited to be joining the Board at the present time. I look forward to working with Peter and my fellow Board directors as the Company executes its planned business development strategy."

Additional information:

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:

Full name: Ian Roy Johnson

Age: 66 years

Current directorships: Klenitise Ltd, Ergomed plc

Previous directorships held in the past 5 years:

Development Bank of Wales PLC

MDH Defence Ltd

Quantum Pharma PLC

Biofortuna Ltd

Cyprotex PLC

Lumora Ltd

Celsis Group Ltd

Toximet Ltd

Bioxyquell Ltd

Bioquell UK Ltd

Bioquell SAS

Bioquell Global Logistics (Ireland) Ltd

Bioquell Inc

Bioquell Defence Inc

Bioquell Professional Services Inc

Bioquell Asia Pacific Pte Ltd

Bioquell Technology (Shenzhen) Ltd

Bioquell Technology Canada Ltd

Bioquell SAS Holding

Bioquell PLC

Ergomed PLC

Companies that went into administration and where creditors lost money as a result of liquidation:

Pure Options Solutions - Administrators appointed on 30 November 2010. The estimated deficiency to investors and creditors was approximately £4.5 million.

Toximet Limited - Administrators appointed on 17 November 2015. The estimated deficiency to investors and creditors was approximately £0.8 million.

Enquiries: